Cite
HARVARD Citation
Huober, J. et al. (2022). Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. Journal of clinical oncology. 40 (25), pp. 2946-2956. [Online].